ClinicalTrials.gg
TerminatedNCT00493805Updated Apr 7, 2017Results posted

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

A Phase 4 interventional study of Combination of pegylated interferon alfa-2b and ribavirin and Combination of pegylated interferon alfa-2b and ribavirin in Hepatitis C, Chronic and Insulin Resistance, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Slow Enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
25th of 39
59 · median 99
Started
2007
with 3 others
Phase 4
10 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 25th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 4, and was the 18th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1. The study consists of two parts: (1) a noninterventional arm (HOMA IR \<= 2) and (2) an interventional arm (HOMA IR > 2), where HOMA IR is the insulin resistance index for the participants calculated by fasting insulin (uU/mL) x [fasting glucose (mmol/L)/22.5]. Participants in the noninterventional arm are treated according to the European labeling and response rates are evaluated at Month 1 (optional), 3, 6, 12, and follow up. Participants in the interventional arm are treated with PEG-Intron 1.5 ug/kg (subcutaneous) once weekly plus weight-based REBETOL 800-1400 mg (oral capsules) daily for a variable period depending on their response at Week 12: (1) HCV-RNA positive with \< 2-log drop in viral load, treatment will be discontinued; (2) HCV-RNA positive with >= 2-log drop in viral load; participants will be randomized (1:1) to Group A (stop treatment at Week 48) or Group B (stop treatment at Week 72); and (3) HCV-RNA negative, treatment will be changed to be according to the European labeling and response rates will be evaluated at Month 6, 12, and follow up. All participants will go on with their treatment after Week 12 until the results of the HCV polymerase chain reaction (PCR) are available (maximum of 4 weeks).

03

Conditions studied

  • Hepatitis C, Chronic
  • Insulin Resistance

Keywords

  • homeostasis model assessment of insulin resistance
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male and female participants with newly diagnosed chronic
  • age 18-65
  • HCV-RNA positive in serum as measured by PCR
  • Genotype 1
  • levels according to European labeling
  • in women of child-bearing age, pregnancy must be excluded prior to entry into the study, and the use of a safe device must be documented; sexually active male participants must practice a method of contraception considered acceptable (vasectomy, condom plus spermicide, plus relationship with a female partner who practices an acceptable method of contraception)
  • Lab parameters:

    • : >=12 g/dL (women) or >= 13 g/dL (men)
    • leukocytes >= 3,000/µL
    • >= 100,000/µL
    • PT//coagulation must be within normal limits or clinically acceptable to the investigator/sponsor
    • Albumin must be within normal limits or clinically acceptable to the investigator/sponsor
    • creatinine must be within normal limits or clinically acceptable to the investigator/sponsor
    • uric acid must be within normal limits or clinically acceptable to the investigator/sponsor
  • antinuclear antibodies \<= 1:160
  • signed

Exclusion criteria

Exclusion Criteria:

  • refusal by women of child-bearing age or by sexually active participants to use a safe
  • breast-feeding women
  • cirrhosis stage B and C according to
  • signs of decompensated liver disease
  • confirmed co-infection with or
  • existing psychiatric comorbidity
  • alcohol abuse
  • active malignant disease or suspicion or history of malignant disease within 5 previous years (except for adequately treated basal cell carcinoma)
  • existing psoriasis or other dermatological disorder
  • treatment with a study drug within the last 30 days
  • any uncontrolled underlying medical conditions
  • abnormalities and/or significant cardiovascular dysfunction within the last 6 months. In case of other suspected heart disease, a cardiological examination is required.
  • any liver disorder of other genesis than the study indication (with regard to elevated iron levels, only participants with manifest hemochromatosis are excluded)
  • disorder (except LKM-positive participants).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Interventional Study arm (with insulin resistance)

    HOMA IR (homeostasis model assessment-estimated insulin resistance) of \> 2 These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment.

    Drug: Combination of pegylated interferon alfa-2b and ribavirin

  • Experimental
    Non interventional study arm (without insulin resistance)

    HOMA IR \<= 2 These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to European labeling).

    Drug: Combination of pegylated interferon alfa-2b and ribavirin

Interventions

  • DrugCombination of pegylated interferon alfa-2b and ribavirin

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization. 2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization

    Also known as: (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol

  • DrugCombination of pegylated interferon alfa-2b and ribavirin

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks 2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks

    Also known as: (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol

06

What researchers measure

Primary outcomes

  1. Early Virological Response in Participants With and Without Insulin Resistance

    Early Virological Response (EVR) defined as HCV PCR at Week 12 either negative or at least 2 log units less than baseline in participants with and without insulin resistance.

    Time frame: At Week 12 (after start of therapy)

Secondary outcomes

  1. Sustained Virological Response (PCR 24 Weeks After End of Treatment)

    Sustained virological response (SVR) was defined as undetectable HCV RNA in serum at the end of follow-up (24 weeks after end of therapy) according to a polymerase chain reaction (PCR) assay.

    Time frame: Up to 24 weeks following 48 or 72 weeks of therapy

07

Results

Posted Feb 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneNon Interventional Arm HOMA IR <= 2Interventional Arm HOMA IR > 2
Started1742
Completed1742
Not completed00

Outcome measures

PrimaryEarly Virological Response in Participants With and Without Insulin Resistance

Early Virological Response (EVR) defined as HCV PCR at Week 12 either negative or at least 2 log units less than baseline in participants with and without insulin resistance.

Time frame:
At Week 12 (after start of therapy)
Reported as:
Number · Participants
Early Virological Response in Participants With and Without Insulin Resistance
ParticipantsNon Interventional Arm HOMA IR <= 2Interventional Arm HOMA IR > 2
Early Virological Response in Participants With and Without Insulin Resistance1024
SecondarySustained Virological Response (PCR 24 Weeks After End of Treatment)

Sustained virological response (SVR) was defined as undetectable HCV RNA in serum at the end of follow-up (24 weeks after end of therapy) according to a polymerase chain reaction (PCR) assay.

Time frame:
Up to 24 weeks following 48 or 72 weeks of therapy
Reported as:
Number · Participants
Sustained Virological Response (PCR 24 Weeks After End of Treatment)
ParticipantsNon Interventional Arm HOMA IR <= 2Interventional Arm HOMA IR > 2
Sustained Virological Response (PCR 24 Weeks After End of Treatment)13

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non Interventional Arm HOMA IR <=2—3/17 (17.6%)15/17 (88.2%)
Interventional Arm HOMA IR >2—4/42 (9.5%)37/42 (88.1%)
Most frequent serious events
Most frequent serious events
EventNon Interventional Arm HOMA IR <=2Interventional Arm HOMA IR >2
ANAEMIABlood and lymphatic system disorders1/170/42
NEUTROPENIABlood and lymphatic system disorders1/171/42
SUICIDE ATTEMPTPsychiatric disorders1/170/42
CORONARY ARTERY DISEASECardiac disorders0/171/42
HYPERTHYROIDISMEndocrine disorders0/171/42
NON-CARDIAC CHEST PAINGeneral disorders0/171/42
GASTROENTERITISInfections and infestations0/171/42
Most frequent other events
Showing 10 of 47
Most frequent other events
EventNon Interventional Arm HOMA IR <=2Interventional Arm HOMA IR >2
LEUKOPENIABlood and lymphatic system disorders8/1713/42
NEUTROPENIABlood and lymphatic system disorders6/1712/42
HEADACHENervous system disorders3/1714/42
INFLUENZA LIKE ILLNESSGeneral disorders5/1713/42
PRURITUSSkin and subcutaneous tissue disorders4/1711/42
ANAEMIABlood and lymphatic system disorders1/1710/42
DEPRESSIONPsychiatric disorders4/175/42
ALOPECIASkin and subcutaneous tissue disorders4/176/42
NAUSEAGastrointestinal disorders3/178/42
FATIGUEGeneral disorders2/178/42

Baseline characteristics

Age, Customized
Age, Customized(Participants)Total for Interventional Arm and Non Interventional Arm
Between 18 and 65 years59
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Total for Interventional Arm and Non Interventional Arm
Male35
Female24
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2007
First posted
Jun 28, 2007
Start
Apr 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Feb 9, 2011
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00493805
Responsible party
Sponsor
First posted
Jun 28, 2007
Start date
Apr 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Feb 9, 2011
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion